Paired box 2 upregulates androgen receptor gene expression in androgen-independent prostate cancer

FEBS Journal

Volumn 281, Issue 19, 2014, Pages 4506-4518

  Ito, Saya ^a   Ueda, Takashi ^a   Ueno, Akihisa ^a   Nakagawa, Hideo ^a   Taniguchi, Hidefumi ^a   Hongo, Fumiya ^a   Kamoi, Kazumi ^a   Okihara, Koji ^a   Kawauchi, Akihiro ^a   Miki, Tsuneharu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Androgen receptor; DNA methylation; Gene expression; PAX2; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; DNA; PAX2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR PAX2;

ADULT; AGED; ANDROGEN RECEPTOR GENE; ARTICLE; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; CELL GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; EPIGENETICS; GENE; GENE EXPRESSION; GENE LOCUS; HUMAN; HUMAN TISSUE; MALE; PAIRED BOX 2 GENE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROSTATECTOMY; TUMOR XENOGRAFT; UPREGULATION; VERY ELDERLY; ANIMAL; CANCER TRANSPLANTATION; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; MIDDLE AGED; MOUSE; NEOPLASM; PHYSIOLOGY; PROMOTER REGION; PROSTATE TUMOR; SCID MOUSE; TUMOR CELL LINE;

AGED; AGED, 80 AND OVER; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, SCID; MIDDLE AGED; NEOPLASM TRANSPLANTATION; NEOPLASMS, HORMONE-DEPENDENT; PAX2 TRANSCRIPTION FACTOR; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; UP-REGULATION;

EID: 84912122975     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12959     Document Type: Article

References (44)

1. Siegel C (2011) Re: A clinically relevant approach to imaging prostate cancer: review. J Urol 186, 2255.
2. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP & Zattoni F (2008) EAU guidelines on prostate cancer. Eur Urol 53, 68-80.
3. Green SM, Mostaghel EA & Nelson PS (2012) Androgen action and metabolism in prostate cancer. Mol Cell Endocrinol 360, 3-13.
4. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P et al. (1995) The nuclear receptor superfamily: the second decade. Cell 83, 835-839.
5. Claessens F, Verrijdt G, Schoenmakers E, Haelens A, Peeters B, Verhoeven G & Rombauts W (2001) Selective DNA binding by the androgen receptor as a mechanism for hormone-specific gene regulation. J Steroid Biochem Mol Biol 76, 23-30.
6. Cleutjens KB, van Eekelen CC, van der Korput HA, Brinkmann AO & Trapman J (1996) Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J Biol Chem 271, 6379-6388.
7. Schuur ER, Henderson GA, Kmetec LA, Miller JD, Lamparski HG & Henderson DR (1996) Prostatespecific antigen expression is regulated by an upstream enhancer. J Biol Chem 271, 7043-7051.
8. Pang S, Dannull J, Kaboo R, Xie Y, Tso CL, Michel K, deKernion JB & Belldegrun AS (1997) Identification of a positive regulatory element responsible for tissuespecific expression of prostate-specific antigen. Cancer Res 57, 495-499.
9. Cleutjens KB, van der Korput HA, van Eekelen CC, van Rooij HC, Faber PW & Trapman J (1997) An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. Mol Endocrinol 11, 148-161.
10. Warnmark A, Treuter E, Wright AP & Gustafsson JA (2003) Activation functions 1 and 2 of nuclear receptors: molecular strategies for transcriptional activation. Mol Endocrinol 17, 1901-1909.
11. Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, Block D, Zhang J, Soden R, Hayakawa M, Kreiman G et al. (2004) A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci USA 101, 6062-6067.
12. Sobel RE & Sadar MD (2005) Cell lines used in prostate cancer research: a compendium of old and new lines-part 1. J Urol 173, 342-359.
13. Cai C, He HH, Chen S, Coleman I, Wang H, Fang Z, Chen S, Nelson PS, Liu XS, Brown M et al. (2011) Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell 20, 457-471.
14. Li Y, Wang L, Zhang M, Melamed J, Liu X, Reiter R, Wei J, Peng Y, Zou X, Pellicer A et al. (2009) LEF1 in androgen-independent prostate cancer: regulation of androgen receptor expression, prostate cancer growth, and invasion. Cancer Res 69, 3332-3338.
15. Jarrard DF, Kinoshita H, Shi Y, Sandefur C, Hoff D, Meisner LF, Chang C, Herman JG, Isaacs WB & Nassif N (1998) Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. Cancer Res 58, 5310-5314.
16. Heinlein CA & Chang C (2004) Androgen receptor in prostate cancer. Endocr Rev 25, 276-308.
17. Ueda T, Ito S, Shiraishi T, Kulkarni P, Ueno A, Nakagawa H, Kimura Y, Hongo F, Kamoi K, Kawauchi A et al. (2013) Hyper-expression of PAX2 in human metastatic prostate tumors and its role as a cancer promoter in an in vitro invasion model. Prostate 73, 1403-1412.
18. Horoszewicz JS, Leong SS, Chu TM, Wajsman ZL, Friedman M, Papsidero L, Kim U, Chai LS, Kakati S, Arya SK et al. (1980) The LNCaP cell line-a new model for studies on human prostatic carcinoma. Prog Clin Biol Res 37, 115-132.
19. Sramkoski RM, Pretlow TG 2nd, Giaconia JM, Pretlow TP, Schwartz S, Sy MS, Marengo SR, Rhim JS, Zhang D & Jacobberger JW (1999) A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim 35, 403-409.
20. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC & Chung LW (1994) Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 54, 2577-2581.
21. Stone KR, Mickey DD, Wunderli H, Mickey GH & Paulson DF (1978) Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 21, 274-281.
22. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF & Jones LW (1979) Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17, 16-23.
23. Tepper CG, Boucher DL, Ryan PE, Ma AH, Xia L, Lee LF, Pretlow TG & Kung HJ (2002) Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res 62, 6606-6614.
24. Dehm SM & Tindall DJ (2011) Alternatively spliced androgen receptor variants. Endocr Relat Cancer 18, R183-R196.
25. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL & Tindall DJ (2008) Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 68, 5469-5477.
26. Kinoshita H, Shi Y, Sandefur C, Meisner LF, Chang C, Choon A, Reznikoff CR, Bova GS, Friedl A & Jarrard DF (2000) Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer. Cancer Res 60, 3623-3630.
27. Bhutani N, Burns DM & Blau HM (2011) DNA demethylation dynamics. Cell 146, 866-872.
28. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind L et al. (2009) Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324, 930-935.
29. Williams K, Christensen J, Pedersen MT, Johansen JV, Cloos PA, Rappsilber J & Helin K (2011) TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity. Nature 473, 343-348.
30. Wu H, D'Alessio AC, Ito S, Xia K, Wang Z, Cui K, Zhao K, Sun YE & Zhang Y (2011) Dual functions of Tet1 in transcriptional regulation in mouse embryonic stem cells. Nature 473, 389-393.
31. Simon JA & Kingston RE (2009) Mechanisms of polycomb gene silencing: knowns and unknowns. Nat Rev Mol Cell Biol 10, 697-708.
32. Grzenda A, Lomberk G, Zhang JS & Urrutia R (2009) Sin3: master scaffold and transcriptional corepressor. Biochim Biophys Acta 1789, 443-450.
33. Patel SR, Kim D, Levitan I & Dressler GR (2007) The BRCT-domain containing protein PTIP links PAX2 to a histone H3, lysine 4 methyltransferase complex. Dev Cell 13, 580-592.
34. Patel SR, Ranghini E & Dressler GR (2014) Mechanisms of gene activation and repression by Pax proteins in the developing kidney. Pediatr Nephrol 29, 589-595.
35. Wang Q, Carroll JS & Brown M (2005) Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. Mol Cell 19, 631-642.
36. Schwab KR, Patel SR & Dressler GR (2011) Role of PTIP in class switch recombination and long-range chromatin interactions at the immunoglobulin heavy chain locus. Mol Cell Biol 31, 1503-1511.
37. Dressler GR & Douglass EC (1992) Pax-2 is a DNA-binding protein expressed in embryonic kidney and Wilms tumor. Proc Natl Acad Sci USA 89, 1179-1183.
38. Ward TA, Nebel A, Reeve AE & Eccles MR (1994) Alternative messenger RNA forms and open reading frames within an additional conserved region of the human PAX-2 gene. Cell Growth Differ 5, 1015-1021.
39. Tavassoli K, Ruger W & Horst J (1997) Alternative splicing in PAX2 generates a new reading frame and an extended conserved coding region at the carboxy terminus. Hum Genet 101, 371-375.
40. Busse A, Rietz A, Schwartz S, Thiel E & Keilholz U (2009) An intron 9 containing splice variant of PAX2. J Transl Med 7, 36.
41. Ito S, Fujiyama-Nakamura S, Kimura S, Lim J, Kamoshida Y, Shiozaki-Sato Y, Sawatsubashi S, Suzuki E, Tanabe M, Ueda T et al. (2012) Epigenetic silencing of core histone genes by HERS in Drosophila. Mol Cell 45, 494-504.
42. Yamagata K, Fujiyama S, Ito S, Ueda T, Murata T, Naitou M, Takeyama K, Minami Y, O'Malley BW & Kato S (2009) Maturation of microRNA is hormonally regulated by a nuclear receptor. Mol Cell 36, 340-347.
43. Wu H, Chen Y, Liang J, Shi B, Wu G, Zhang Y, Wang D, Li R, Yi X, Zhang H et al. (2005) Hypomethylation-linked activation of PAX2 mediates tamoxifen-stimulated endometrial carcinogenesis. Nature 438, 981-987.
44. Takaha N, Sowa Y, Takeuchi I, Hongo F, Kawauchi A & Miki T (2012) Expression and role of HMGA1 in renal cell carcinoma. J Urol 187, 2215-2222.